migration and invasion, and studies using nude mice models also demonstrated that the expression of TMEPAI promoted cancer growth. Our mechanistic study showed that TMEPAI regulates TGF-β signalling pathway through the modulation of TβRI protein levels by promoting its lysosomal degradation. 11 Our results also showed that expression of TMEPAI improves lysosomal stability against stress-induced lysosomal rupture and promotes autophagy. 12 Moreover, our study indicated that CI-M6PR
and clathrin mediated TMEPAI transport from the Golgi into the endolysosomal pathway, and ubiquitination modification of TMEPAI is an important signal for TMEPAI lysosomal trafficking. 13 Our recent research found that the sequence between −298 and +24 includes the basal promoter activity for TMEPAI. Furthermore, Sp1 promotes TMEPAI expression and contributes to cell proliferation. 14 All these studies indicated that TMEPAI could be a novel anti-cancer drug screening target.
In the present study, a firefly luciferase reporter screening system driven by TMEPAI promoter was established, and purified compounds were screened. It was found that JHY-A007-50 could effectively inhibit the expression of TMEPAI. Further results have shown that JHY-A007-50 could induce G1 phase arrest in cancer cells that expressed high levels of TMEPAI. These results have demonstrated that TMEPAI is a novel anti-cancer therapeutic target, and JHY-A007-50 could be a potential anti-tumour drug for cancer expressing high levels of TMEPAI.
| MATERIAL S AND ME THODS

| Materials and antibodies
All materials were purchased from Sigma (St. Louis, MO, USA) unless otherwise stated. Antibodies were purchased from the following sources: Ki-67, CDK2, Cyclin E1, p53, Legumain, SM22, Histone and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Sp1
(Proteintech Group, Rosemont, IL, USA). Fluorophore (D&S488 and D&R647) and HRP-conjugated secondary antibodies were obtained from Invitrogen (Carlsbad, CA, USA).
| Cell culture
HeLa, MGC-803, HepG2, L02 cells were grown at 37°C and 5% CO 2 
| Screening of potential inhibitors of TMEPAI expression
HeLa cells were plated at 2 × 10 6 cells/well in a 6-cm-plate. After 24 h, cells were transfected with 2 μg of pGL3-TMEPAI promoter plasmid or 2 μg of pGL3 vector plasmid per well plus 0.1 μg of pCMV-β-galactosidase plasmid. After 24 h, the transfected cells were plated onto the 96-well plates 5 × 10 3 cells/well. Cells were treated with compounds at concentrations of 5 μM in DMEM containing 3% FBS for 24 h, and luciferase activity was detected as described. 14 
| MTT assay
Cell viability was measured using the MTT (3-[4,5-dimethylthiazol -2-yl]-2,5-diphenyltetrazolium bromide; thiazolyl blue) assay. Cells were plated (5000 cells/well) with 200 μL of cell growth medium in 96-well plates and cultured for the indicated time. MTT was added at a final concentration of 0.5 mg/mL in PBS and incubated for 4 h at 37°C. The medium was then removed and the remaining blue precipitate was solubilized in dimethylsulfoxide (DMSO). The absorbance was read at 570 nm in a microplate reader. All the MTT data were averaged from 3 independent experiments. The IC 50 value was assessed using probit regression analysis by spss statistical software.
| Western blot
Cultured cells were washed twice using PBS before addition of ice cold lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM NaF, 1 mM phenylmethylsulphonyl fluoride, 4 mg/mL leupeptin and 1 mg/mL aprotinin, and 1% Nonidet P-40). Bradford method was used to measure the protein level, and equal amounts of protein were loaded into each well and separated by 7%, 10% or 12% SDS-PAGE gel, followed by transfer to PVDF membranes. These PVDF membranes were blocked in PBST buffer containing 5% non-fat milk for 1 h at room temperature. Blots were then incubated at 4°C with primary antibodies overnight. Secondary antibody incubation was carried out for 1 h at room temperature. Finally, Odyssey infrared laser imaging system (LI-COR Biosciences, Lincoln, NE, USA) was used to image the results.
| RNA extract and RT-PCR
Total RNA was isolated from cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.
RNA was quantified by measuring the absorbance (A260 nm). One microgram of RNA was reverse transcribed with oligo (dT) primers using a reverse transcription system. The single-stranded cDNA was amplified by PCR using the specific primers. PCR was performed for 30 cycles (each cycle consisting of 94°C for 30 s, 54°C
for 30 s and 72°C for 30 s). The PCR products were analysed by electrophoresis on a 1% agarose gel. Primer sequences used were shown in Table 1 .
| Chromatin immunoprecipitation assays
HeLa cells were cultured in the 10-cm dishes and treated with 4 μM JHY-A007-50 for 24 h, with DMSO as the negative control. Cells were processed for ChIP assay as described previously. 14 Briefly, the IgG or anti-Sp1 was used for the immunoprecipitation. Then, the immunoprecipitated DNAs were purified and used for PCR. The primers for detection of TMEPAI promoter DNA sequence containing Sp1-binding sites are as follows: forward, 5′-CGGGTCTACGTGGGCCGCCTAGC-3′; reverse, 5′-AGGTTCCCCCGCACCCCCTCC-3′. Analysis of the PCR products was performed on a 1.2% agarose gel electrophoresis. 
| Colony formation assay
| Cell cycle analysis
Cell cycle analysis was performed using Cell Cycle Kit (Beyotime, China) following the manufacturer's instructions. The percentages of cells in the different cell cycle phases were measured using a flow cytometer. 
| Immunofluorescence assay
| EdU incorporation assay
| RNA interference
Lentiviral vectors expressing TMEPAI shRNAs (TRC332: 5′-CCGG ATCACGGAGCTGGAGTTTGTTCTCGAGAACAAACTCCAGCTCCG TGATTTTTT-3′ or the non-target shRNA control vector (SHC002)
was obtained from Sigma and the knockdown level was tested by
Sigma. The TMEPAI shRNA has been tested to inhibit the expression of TMEPAI specifically. 11 The lentiviruses were obtained according to the manufacturers' protocol. Cells were infected with lentiviruses for 3 d before experiments were performed.
| Statistical analysis
All the experiments were repeated at least 3 times, the average values used as results and a set of representative figures shown as illustration. Statistical analysis was performed using the χ 2 test or
Fisher's exact test and Spearman's rank correlation coefficient analysis. P < .05 indicated that the difference was significant, and P < .01 indicated that the difference was highly significant.
| RE SULTS
| Compound JHY-A007-50 inhibits TMEPAI promoter activity
It has been shown that TMEPAI is highly expressed in many kinds of cancer cells and plays an important role in tumourigenesis, which makes it a potential drug screening target for cancer therapy. To obtain potential candidate inhibitors capable of inhibiting the expression of TMEPAI, a luciferase assay system driven by TMEPAI promoter was established and screened against a compound library ( Figure 1A ). JHY-A007-89 (see structure in Figure 1B ) was found to have significant inhibitory effects on the promoter activity of TMEPAI, indicating that JHY-A007-89 may be a potential inhibitor of TMEPAI expression. Further analysis also confirmed that JHY-A007-89 markedly inhibited the TMEPAI luciferase reporter activity in a dose-dependent manner ( Figure 1C ).
To explore the possibility of obtaining more effective compounds, various derivatives of the lead compound JHY-A007-89 (Table S1 ) were synthesized and their inhibitory effects on TMEPAI gene promoter activity were detected in HeLa cells at a concentration of 4 μM ( Figure 2A ). It was found that JHY-A007-50 (see structure in Figure 2B ) could inhibit TMEPAI promoter activity more potently, and the inhibitory concentration (IC50) value was 3.5 μmol/L ( Figure 2C ).
| Compound JHY-A007-50 downregulates TMEPAI expression in cancer
To confirm the inhibitory effect of JHY-A007-50 on the expression of TMEPAI, the levels of TMEPAI mRNA and protein in HeLa cells Figure 3H , JHY-A007-50 did not affect the expression of LGMN and SM22 ( Figure 3H ). These results suggest that JHY-A007-50 is an efficient and specific inhibitor of TMEPAI expression in cancer cells.
Our previous study showed that transcription factor Sp1 could promote the expression of TMEPAI. 14 To test whether JHY-A007-50 targets Sp1 to regulate the expression of TMEPAI, the protein level of Sp1 in cytoplasm and nucleus with or without this compound treatment was examined. The result showed that the expression or the nucleus translocation of Sp1 was not altered by treating with JHY-A007-50 ( Figure 3I ), which indicates Sp1 is not the target of JHY-A007-50. Furthermore, whether Sp1 binding to TMEPAI promoter is affected by compound JHY-A007-50 was analysed using CHIP assay. As shown in Figure 3J , Sp1 binding to TMEPAI promoter is not affected by treating with compound JHY-A007-50.
| Compound JHY-A007-50 inhibits the cell proliferation of HeLa cells
Previous reports found that TMEPAI plays an important role in tumourigenesis, which could be an important target for cancer therapy. These results suggest that compound JHY-A007-50 may have anticancer activity due to its ability to downregulate TMEPAI expression.
To further detect the mechanism by which JHY-A007-50 reduced the viability of cancer cells, we evaluated the effects of JHY-A007-50 using a colony formation assay, EdU incorporation assay and Ki-67 fluorescence assay. The colony formation assay showed that JHY-A007-50 reduced the colony formation rate ( Figure 5A-C) .
The EdU incorporation in HeLa cells treated with JHY-A007-50 was also inhibited (Figure 5D-F) . Antigen Ki-67 is a nuclear protein that is strictly associated with cell proliferation. 19 Fluorescence assay data showed that JHY-A007-50 reduced the expression of Ki-67
( Figure 5G-I ). Taken together, these results show that JHY-A007-50
has an inhibitory effect on cancer cell proliferation. Moreover, the effect of JHY-A007-50 on cell migration was also investigated by Wound-Healing assay, and the results showed that JHY-A007-50
can significantly inhibit HeLa cell migration ( Figure 5J ).
| JHY-A007-50 induces G1-phase arrest in cancer cells
The cell cycle plays an important role in cell proliferation, and many anti-cancer drugs could inhibit cell proliferation through inducing cell cycle arrest. 20, 21 To examine whether the anti-proliferation effect of JHY-A007-50 is associated with cell cycle arrest, we measured the cell cycle distribution in JHY-A007-50-treated cells using flow cytometry. The results showed that in HeLa cells the cell population in the G1 phase was 40.58% in the control group; however, upon treatment with JHY-A007-50, the percentage of G1 phase cells increased to 59.16% ( Figure 6A ). Similar result was also found in MCF-7 cells, where the percentage of G1 phase cells increased from 54.83% to 64.54% ( Figure 6B ). This suggested that JHY-A007-50 induces cell cycle arrest at the G1 phase.
Since cyclins D, E, and CDK2 have a key role in regulating the progression of G1 and S phase, then the expression levels of these proteins were measured. As shown in Figure 6C , the expression of cyclin E1 and CDK2 was decreased upon treated with JHY-A007-50. 
| D ISCUSS I ON
TMEPAI is abnormally activated in many cancers and previous studies have suggested that downregulating the expression of TMEPAI could subsequently depress cell proliferation and colony formation.
These results indicate that TMEPAI could be a potential novel drug screening target for cancer therapy. These results suggest that JHY-A007-50 inhibits cell proliferation partially through the downregulation of TMEPAI expression. Our previous study had indicated that TMEPAI could increase lysosome stability and promotes autophagy 12 and so a future study will focus on the effects that JHY-A007-50 may have on autophagy and its in vivo anti-tumour activity.
In conclusion, these results indicate that JHY-A007-50 is a novel and potent inhibitor of TMEPAI expression. Additionally, the antitumour effect of JHY-A007-50 may be achieved through cell cycle arrest at the G1 phase. These results demonstrate that JHY-A007-50
could be a very promising anti-cancer drug candidate for TMEPAI high-expressing tumours.
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